EpilepsyGTx and Viralgen have entered a manufacturing collaboration to support development of EPY201, an investigational AAV9-based gene therapy for focal refractory epilepsy planned to enter first-in-human testing in 2027.
|Slideshows|December 4, 2016
AES 2016: Pregnancy in Women with Epilepsy
Author(s)Samantha J. Peterson
Careful planning and monitoring is important for women with epilepsy who become pregnant. Several studies from AES 2016 address pregnancy issues.
Advertisement
Studies presented at the 2016 American Epilepsy Society Scientific Sessions examined pregnancy issues in women with epilepsy. One study looked at predictors of unintended pregnancy, another discussed antiepileptic drug prescribing patterns, and two studies reported on specific drugs, brivaracetam and lamotrigine, taken during pregnancy.Â
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
The FDA extended its review of relutrigine for SCN2A- and SCN8A-related epilepsies by three months, pushing the PDUFA date to December 27, 2026.
The FDA lifted a clinical hold on simufilam, clearing Filana Therapeutics, formerly Cassava Sciences, to begin a phase 2a study in TSC-related epilepsy.
Xenon Pharmaceuticals submitted an FDA new drug application for azetukalner, a KV7 potassium channel opener, as adjunctive therapy for focal seizures in epilepsy.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tavapadon for the Treatment of Parkinson Disease
2
SHIELD Trial Advances Combination Antiviral for Long COVID
3
Inebilizumab Shows Durable Benefit in MuSK+ Generalized Myasthenia Gravis at AANEM 2026
4
Gefurulimab Cuts Hospitalizations, Sustains Response in Phase 3 PREVAIL Trial of Myasthenia Gravis
5